Evidence map›Paper›PMID 33802226›Full record

ArticlePharmaceutics2021

Taking Particle Tracking into Practice by Novel Software and Screening Approach: Case-Study of Oral Lipid Nanocarriers.

María Plaza-Oliver, Emilio L Cano, María Mar Arroyo-Jimenez, Matías Gámez, María Victoria Lozano-López, Manuel J Santander-Ortega

Abstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

María Plaza-OliverCellular Neurobiology and Molecular Chemistry of the Central Nervous System Group, Faculty of Pharmacy, University of Castilla-La Mancha (UCLM), 02071 Albacete, Spain.
Emilio L CanoQuantitative Methods and Socio-economic Development Group, Institute for Regional Development (IDR), University of Castilla-La Mancha (UCLM), 02006 Albacete, Spain.ORCID 0000-0002-6101-9755
María Mar Arroyo-JimenezCellular Neurobiology and Molecular Chemistry of the Central Nervous System Group, Faculty of Pharmacy, University of Castilla-La Mancha (UCLM), 02071 Albacete, Spain.
Matías GámezQuantitative Methods and Socio-economic Development Group, Institute for Regional Development (IDR), University of Castilla-La Mancha (UCLM), 02006 Albacete, Spain.ORCID 0000-0002-6772-9301
María Victoria Lozano-LópezCellular Neurobiology and Molecular Chemistry of the Central Nervous System Group, Faculty of Pharmacy, University of Castilla-La Mancha (UCLM), 02071 Albacete, Spain.ORCID 0000-0001-7774-732X
Manuel J Santander-OrtegaCellular Neurobiology and Molecular Chemistry of the Central Nervous System Group, Faculty of Pharmacy, University of Castilla-La Mancha (UCLM), 02071 Albacete, Spain.

Funding

Spanish Research Agency AEI/FEDER UE MTM2017-86875-C3-1-R.University of Castilla-La Mancha (UCLM) (01110AB026 and 01110AB039) (OE154 and 2018/152504)
6 · The paper itself

Abstract

The success on the design of new oral nanocarriers greatly depends on the identification of the best physicochemical properties that would allow their diffusion across the mucus layer that protects the intestinal epithelium. In this context, particle tracking (PT) has arisen in the pharmaceutical field as an excellent tool to evaluate the diffusion of individual particles across the intestinal mucus. In PT, the trajectories of individual particles are characterized by the mean square displacement (

Indexed as

data processingdiffusionoral lipid nanocarriersparticle trackingR softwarescreening of trajectories

Identifiers

PMID33802226
PMCPMC8001040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.